Tecentriq 1 200 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tiragolumab placebo, Tiragolumab
BO42592
Phase 3 small_molecule active
Quick answer
Tecentriq 1 200 mg concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Tiragolumab placebo, Tiragolumab for Non-squamous non-small cell lung cancer (NSCLC) is a Phase 3 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Non-squamous non-small cell lung cancer (NSCLC)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active